Recently, rituximab (an anti-CD20 monoclonal antibody) has been applied to the therapy for AHA, with positive results.[25] The sustained reaction is considered to be retained if FVIII inhibitor is less than 0.6 BU/mL and the activity of FVIII is greater than 50%, and if partial remission is established by an inhibitor titer of less than 5 BU/mL and FVIII activity of 30%. This evidence concerns the gene F8 and autoimmune hemolytic anemia.